MedTrace Logo

Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn

NCT04328636 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-08-18

No results posted yet for this study

Summary

The aim of this pilot randomized controlled blinded study is to evaluate the feasibility of using nebulized magnesium sulfate in the treatment of PPHN.

Conditions

  • Persistent Fetal Circulation
  • Persistent Pulmonary Hypertension of the Newborn
  • PPHN

Interventions

DRUG

Nebulized Magnesium Sulfate

Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes

DRUG

Intravenous Magnesium Sulfate

Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Principal Investigators

  • Elsayed Abdelkreem, MD, PhD · Faculty of Medicine, Sohag University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Hours
Max Age
72 Hours
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2020-07-01
Completion
2020-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04328636 on ClinicalTrials.gov